Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foistar (Camostat Mesylate) with Remdesivir in Severe COVID-19
NCT04713176Phase 3Terminated
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camostat mesilate in coronavirus disease 2019 (COVID-19), sponsored by Daewoong Pharmaceutical. Started Feb 2021; status: terminated.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04713176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713176.